Product Information
PREMPHASE 0.625-5 MG TABLET is a brand product labeled by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., priced at $8.6814 per EA under NDC 00046257512. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Nov 17, 1995.
NDC
00046257512
Classification
Brand
Dosage Form
KIT
Effective Date
1/1/2026
Approval Type
New Drug (NDA)
FDA Application
NDA020527FDA Approved
11/17/1995
On Market Since
3/1/2012
Price Statistics
The NADAC for PREMPHASE 0.625-5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 156.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.6814 per EA |
|---|---|
| All-time high | $8.6814 (Sep 30, 2026) |
| All-time low | $3.3889 (Nov 28, 2013) |
| 52-week high | $8.6814 |
| 52-week low | $8.4479 |
| Median price | $6.9125 |
| Average price | $6.7203 |
| Largest weekly change | +9.5% (Jun 11, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the conjugated estrogens and medroxyprogesterone acetate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
conjugated estrogens and medroxyprogesterone acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PREMPHASE 0.625-5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PREMPHASE 0.625-5 MG TABLET, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., is $8.6814 per EA (NDC 00046257512), effective Sep 30, 2026.
How has the price of PREMPHASE 0.625-5 MG TABLET changed over time?
Over the history we have for it, the NADAC for PREMPHASE 0.625-5 MG TABLET has risen 156.2%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PREMPHASE 0.625-5 MG TABLET?
Since Nov 28, 2013, the NADAC for PREMPHASE 0.625-5 MG TABLET has ranged from a low of $3.3889 (Nov 28, 2013) to a high of $8.6814 (Sep 30, 2026), with a median of $6.9125 per EA.
Are there cheaper alternatives to PREMPHASE 0.625-5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PREMPHASE 0.625-5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PREMPHASE 0.625-5 MG TABLET?
PREMPHASE 0.625-5 MG TABLET (NDC 00046257512) is labeled by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., and CMS classifies it as a brand product.